Dr. Abhay Kolte / Dr. Shivani Koli / Dr. Surekha Rathod
Librería Samer Atenea
Librería Aciertas (Toledo)
Kálamo Books
Librería Perelló (Valencia)
Librería Elías (Asturias)
Donde los libros
Librería Kolima (Madrid)
Librería Proteo (Málaga)
Metformin, alendronate, and statins have emerged as promising local drug delivery (LDD) agents in the management of chronic periodontitis. These drugs exhibit diverse pharmacological properties that enhance periodontal regeneration and inflammation resolution when used adjunctively with conventional mechanical therapy. Each drug targets critical aspects of periodontitis pathophysiology, including inflammation, oxidative stress, and alveolar bone loss, making them valuable tools in enhancing therapeutic outcomes.The application of metformin, alendronate, and statins as LDD agents shows significant potential in improving clinical, radiographic, and biochemical parameters in chronic periodontitis. While the preliminary findings are promising, the variability in drug concentrations, formulations, and delivery systems calls for further standardization and long-term clinical trials. These agents could serve as valuable adjuncts to scaling and root planing (SRP), offering targeted therapeutic benefits with minimal systemic side effects. Their incorporation into routine periodontal care holds the potential to improve patient outcomes and redefine periodontal therapy strategies.
